FOXO3 has received great attention as a potential prognostic biomarker for overall survival in patients with cancer because several clinical studies with primary tumor specimens have indicated that FOXO3′s nuclear exclusion or downregulation correlates significantly with poor prognosis and survival in breast and ovarian carcinomas (12,32–34). This evidence concerns the gene FOXO3 and cancer.